Cardiovascular Disease

Publications

click to view chapters and sections

Disease Control Priorities in Developing Countries (2nd Edition)

1. 1. Investing in Health
   1. Noncommunicable Disease and Injury
2. 2. Intervention Cost–Effectiveness: Overview of Main Messages
   1. Annex 2.A: Intervention Categories and Pertinent Policy Instruments
3. 5. Science and Technology for Disease Control: Past, Present, and Future
   1. Science, Technology, and Medicine in the 20th Century
4. 7. Economic Approaches to Valuing Global Health Research
   1. The Value of Health Research
5. 11. Fiscal Policies for Health Promotion and Disease Prevention
6. 14. Ethical Issues in Resource Allocation, Research, and New Product Development
7. 15. Cost–Effectiveness Analysis for Priority Setting
   1. Cost-Effectiveness and Population Impact
8. 22. Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy
9. 27. Newborn Survival
10. 30. Diabetes: The Pandemic and Potential Solutions
    1. Lessons and Experience
11. 32. Neurological Disorders
    1. Stroke
    2. Cost-Effectiveness of Interventions in Developing Countries
    3. Recommendations
    4. Research and Development Agenda
    5. Missed Opportunities
    6. Acknowledgments
12. 33. Cardiovascular Disease
    1. Epidemiology of CVD
    2. Burden of Disease
    3. Cost-Effectiveness of Interventions
    4. Research and Development
    5. Conclusions: Pitfalls and Promises
13. 36. Diseases of the Kidney and the Urinary System
    1. Causes of Diseases of the Kidney and Urinary System
    2. Implementation of Control Strategies: Lessons of Experience
    3. Conclusions: Promises and Pitfalls
14. 44. Prevention of Chronic Disease by Means of Diet and Lifestyle Changes
    1. Cost-Effectiveness of Interventions
15. 45. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight
    1. Epidemiology
    2. Burden of the Disease, Condition, or Risk Factor
    3. Interventions
    4. Cost-Effectiveness of Interventions
    5. Economic Benefits of Intervention
    6. Research and Development Agenda
    7. Conclusions
16. 51. Cost–Effectiveness of Interventions for Musculoskeletal Conditions
    1. Treatments
17. 58. School–Based Health and Nutrition Programs
18. 64. General Primary Care
    1. The Scope of General Primary Care Practice
    2. A Research and Development Agenda for General Primary Care

Global Burden of Disease and Risk Factors

1. 1. Measuring the Global Burden of Disease and Risk Factors, 1990—2001
2. 3. The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001
3. 4. Comparative Quantification of Mortality and Burden of Disease Attributable to Selected Risk Factors
   1. Risk Factor Selection
   2. Joint Effects of Multiple Risk Factors
   3. Discussion
4. 6. Incorporating Deaths Near the Time of Birth into Estimates of the Global Burden of Disease

Priorities in Health

1. 5. Cost–Effective Strategies for Noncommunicable Diseases, Risk Factors, and Behaviors
   1. Cardiovascular Disease, Diabetes, High Blood Pressure, Cholesterol, and Bodyweight
   2. Unintentional Injuries
2. 7. Pillars of the Health System

Chapter Presentations

Chapter 02. Intervention Cost-Effectiveness: Overview of Main Messages

1. Neglected Low-Cost Opportunities in Sub-Saharan Africa: Cardiovascular Disease
2. Neglected Low-Cost Opportunities in South Asia: Cardiovascular Disease
3. Cost-effectiveness of Interventions for Cardiovascular Disease and Diabetes in Low- and Middle-Income Countries

Chapter 33. Cardiovascular Disease

1. Cardiovascular Events and Deaths Preventable By Medical Therapy

Chapter 45. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight

1. Cost-effectiveness of Interventions for Cardiovascular Disease in Latin America and the Caribbean*
2. Global Cardiovascular Disease Burden Due to High Blood Pressure, Cholesterol, and Overweight
3. Cost-effectiveness of Interventions for Cardiovascular Disease in Africa*
4. Cost-effectiveness of Interventions for Cardiovascular Disease in Southeast Asia*
5. Cost-effectiveness of Interventions for Cardiovascular Disease in the Western Pacific*
6. Estimates of Cost-effectiveness of a Polypill for Cardiovascular Disease, By Region
7. Estimates of Cost-effectiveness of a Polypill for Cardiovascular Disease in India